Genetic Technologies Limited logo
Genetic Technologies Limited GENE
report update icon

Quarterly report 2024-Q2
added 05-23-2026

Genetic Technologies Limited Income Statement 2024-2011 | GENE

Brief overview of revenue and earnings at Genetic Technologies Limited

The figures are compared over a five-year interval. Revenue at Genetic Technologies Limited moved from 25.4 thousand AUD in 2019 to 7.7 million AUD in 2024. The five-year change reached +30024.1%, while CAGR stood at 213.2%. The annual growth rate indicates an exceptionally strong top-line trend.

The five-year EBITDA result moved by +100%: from −6 million AUD to 0 AUD. EBITDA underperformed the top-line trend. Comparing the endpoints gives EBITDA margins of −23573.7% and 0%. Higher profitability strengthens the quality of operating growth.

The net financial result changed from −6.4 million AUD to −12 million AUD. The negative result deepened, showing weaker final efficiency.

Conclusion

The figures do not all move in the same direction. The strongest signals are an improving EBITDA margin and a larger revenue base. Caution is warranted because of lower net income and limited operating profitability. Further direction will depend on top-line growth, operating profitability, and net income.

Annual Income Statement Genetic Technologies Limited

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- - 133 M 17.7 B 18.2 B 7.35 B 8.38 B 12.2 B 7.55 B 24.4 M 17.4 M 40.1 M 57.6 M 81.5 M

Shares

132 M 101 M 92.2 M 8.54 B 4.16 B 2.64 B 2.44 B 2.12 B 1.72 B 1.92 M 1.03 M 843 K 822 K 723 K

Historical Prices

1.44 2.07 4.37 2.79 3.44 5.76 4.4 8.24 23.3 32.8 49 63.6

Net Income

-12 M -11.8 M -7.13 M -7.08 M -6.29 M -6.43 M -5.46 M -8.4 M -8.46 M -8.81 M -10.1 M -9.3 M -5.29 M 910 K

Revenue

7.66 M 8.69 M 6.79 M 121 K 9.86 K 25.4 K 189 K 519 K 825 K 2.01 M 4.56 M 3.38 M 3.69 M 18.3 M

Cost of Revenue

- - - 361 K 252 K 276 K 300 K 492 K 743 K - - - - -

Gross Profit

- - - -240 K -242 K -251 K -111 K 26.1 K 81.5 K 1.12 M 2.73 M 1.43 M 1.74 M 16.2 M

Interest Expense

17.6 K 29.5 K 15.2 K 16.3 K 37.4 K - - - - - - - - -

EBITDA

- - - - - -6 M -5.67 M -7.55 M -8.17 M -9.52 M -9.51 M -8.75 M -10.5 M 1.66 M

Operating Expenses

- - - - - 5.91 M 5.87 M 7.94 M 8.64 M 10.9 M 12.6 M 10.6 M 12.8 M 15.2 M

General and Administrative Expenses

- - - 4.16 M 4.06 M 3.83 M 3.02 M 3.11 M 3.43 M 4.66 M 4.25 M 6.81 M 6.88 M 7.79 M

All numbers in AUD currency

Quarterly Income Statement Genetic Technologies Limited

2024-Q2 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

132 M 115 M 101 M 9.23 B - 92.2 M - - - 8.54 B - - - 4.16 B - - - 2.64 B - - - 2.44 B - - - 2.12 B - - - 1.72 B - - - - - - - - - - - - - - - - - - - - -

Net Income

-12 M -6.42 M -11.8 M -5.46 M - -7.13 M - - - -7.08 M - - - -6.29 M - - - -6.43 M - - - -5.46 M - - - -8.4 M - - - -8.46 M - - - - - - - - - - - - - - - - - - - - -

Revenue

7.66 M 3.96 M 8.69 M 4.15 M - 6.79 M - - - 121 K - - - 9.86 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - - - - - - 361 K - - - 252 K - - - 276 K - - - 300 K - - - 492 K - - - 743 K - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - -240 K - - - -242 K - - - -251 K - - - -111 K - - - 26.1 K - - - 81.5 K - - - - - - - - - - - - - - - - - - - - -

Operating Income

- - - - - - - - - - - - - -2.64 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

17.6 K - 29.5 K - - 15.2 K - - - 16.3 K - - - 37.4 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - - - - - - - - - - - -2.64 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

- - - - - - - - - 4.16 M - - - 4.06 M - - - 3.83 M - - - 3.02 M - - - 3.11 M - - - 3.43 M - - - - - - - - - - - - - - - - - - - - -

All numbers in AUD currency

The income statement is one of the three key financial reports of a company Genetic Technologies Limited (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
NeoGenomics NeoGenomics
NEO
$ 15.29 -3.72 % $ 1.96 B usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 12.04 4.42 % $ 2.62 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Natera Natera
NTRA
$ 267.76 -0.7 % $ 36.6 B usaUSA
OPKO Health OPKO Health
OPK
$ 1.32 -1.12 % $ 991 M usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 416.3 2.6 % $ 29.2 B schweizSchweiz
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 26.3 -0.53 % $ 24.9 B niderlandNiderland
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Personalis Personalis
PSNL
$ 12.66 3.09 % $ 1.13 B usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Quidel Corporation Quidel Corporation
QDEL
$ 16.77 1.21 % $ 706 M usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Celcuity Celcuity
CELC
$ 86.38 -1.44 % $ 4.04 B usaUSA
Neuronetics Neuronetics
STIM
$ 1.98 0.51 % $ 131 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 43.71 14.72 % $ 2.33 B usaUSA
Waters Corporation Waters Corporation
WAT
$ 377.31 -0.79 % $ 22.5 B usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 163.57 -1.19 % $ 12.8 B irlandaIrlanda
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Soleno Therapeutics Soleno Therapeutics
SLNO
- - $ 2.69 B usaUSA
Exagen Exagen
XGN
$ 4.53 -3.0 % $ 97.7 M usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 233.01 -0.58 % $ 25.9 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Biomerica Biomerica
BMRA
$ 1.49 -6.28 % $ 3.42 M usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 7.27 -1.76 % $ 29 M israelIsrael
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 3.42 -3.93 % $ 111 K usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
Co-Diagnostics Co-Diagnostics
CODX
$ 1.44 -7.69 % $ 1.92 M usaUSA
DexCom DexCom
DXCM
$ 83.45 11.95 % $ 32.6 B usaUSA
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA